CorMedix Inc Asset Resilience Ratio
CorMedix Inc asset resilience ratio. CorMedix Inc (CRMD) has an Asset Resilience Ratio of 0.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CorMedix Inc (CRMD) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CorMedix Inc (2011–2025)
Asset resilience ratio of CorMedix Inc from 2011 to 2025. This chart shows how CorMedix Inc's Asset Resilience Ratio has changed over time. Read CorMedix Inc (CRMD) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CorMedix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CorMedix Inc (CRMD) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.69 Million | 0.45% |
| Total Liquid Assets | $3.69 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: CorMedix Inc maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CorMedix Inc Industry Peers by Asset Resilience Ratio
Compare CorMedix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
CorMedix Inc Asset Resilience Ratio by Year (2011–2025)
CorMedix Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for CorMedix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.45% | $3.69 Million | $826.14 Million | -8.84pp |
| 2024-12-31 | 9.29% | $11.04 Million | $118.85 Million | -30.18pp |
| 2023-12-31 | 39.47% | $32.39 Million | $82.06 Million | +14.25pp |
| 2022-12-31 | 25.22% | $15.64 Million | $62.04 Million | +7.60pp |
| 2021-12-31 | 17.62% | $12.15 Million | $68.95 Million | +8.61pp |
| 2020-12-31 | 9.01% | $4.44 Million | $49.31 Million | -31.64pp |
| 2019-12-31 | 40.66% | $11.98 Million | $29.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $18.83 Million | -- |
| 2017-12-31 | 11.92% | $1.60 Million | $13.45 Million | -43.32pp |
| 2016-12-31 | 55.24% | $12.10 Million | $21.91 Million | -8.28pp |
| 2015-12-31 | 63.52% | $23.57 Million | $37.10 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $5.10 Million | -- |
| 2013-12-31 | 7.45% | $221.00K | $2.97 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.15 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.56 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more